—
C+
C+ The full Closelook — membership. Open the C+ overview

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) — Quality & forensics

As of 2026-09-18 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

54 /100 composite · 7 modules · general weight set

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

2.37 Altman Z-Score

Sits in the grey zone (1.81–2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

7/9 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

-2.67 Beneish M-Score

Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.

Continue: the AMRX chart & overview · the earnings record

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Closelook quality reading?

The composite reads 54/100 across 7 modules, as of 2026-09-18: valuation 42, quality 57, growth 61, balance sheet 39, cash quality 70, capital allocation 24, momentum 89. Closelook scores are research diary readings, not ratings or investment advice.

What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Altman Z-Score?

2.37, which sits in the grey zone (1.81–2.99) as of 2026-09-18. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Piotroski F-Score?

7 of 9, as of 2026-09-18. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

What does Amneal Pharmaceuticals, Inc. Class A Common Stock's Beneish M-Score indicate?

-2.67 — below the −1.78 manipulation-risk threshold, as of 2026-09-18. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.